Pancreas Adenocarcinoma Clinical Trials

20 recruiting

Pancreas Adenocarcinoma Trials at a Glance

21 actively recruiting trials for pancreas adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Not Applicable with 7 trials, with the heaviest enrollment activity in Winston-Salem, Umeå, and Minya. Lead sponsors running pancreas adenocarcinoma studies include Minia University, Wake Forest University Health Sciences, and Central Hospital, Nancy, France.

Browse pancreas adenocarcinoma trials by phase

Treatments under study

About Pancreas Adenocarcinoma Clinical Trials

Looking for clinical trials for Pancreas Adenocarcinoma? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreas Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreas Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 2

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Pancreas AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences64 enrolled1 locationNCT05825066
Recruiting
Phase 2

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Esophageal AdenocarcinomaGastric AdenocarcinomaPancreas Adenocarcinoma+6 more
Yale University54 enrolled1 locationNCT07282912
Recruiting

Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma

Pancreas AdenocarcinomaCachexia
Wake Forest University Health Sciences100 enrolled2 locationsNCT05376592
Recruiting
Phase 2

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic NeoplasmsCancer of Pancreas+4 more
UNC Lineberger Comprehensive Cancer Center45 enrolled1 locationNCT03977233
Recruiting
Phase 4

Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

Neuro Endocrine TumoursPDAC - Pancreatic Ductal AdenocarcinomaPancreas Adenocarcinoma+7 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)400 enrolled1 locationNCT07262957
Recruiting
Phase 2

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Pancreas Adenocarcinoma
Dartmouth-Hitchcock Medical Center35 enrolled1 locationNCT07043270
Recruiting
Phase 2

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Pancreas AdenocarcinomaResectable Pancreatic Cancer
Loma Linda University30 enrolled1 locationNCT03492671
Recruiting
Phase 3

Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

Pancreas CancerPancreas AdenocarcinomaPancreatic Cancer Resectable+3 more
Minia University262 enrolled1 locationNCT07081360
Recruiting
Not Applicable

Genetic Testing Decision Aid

Epithelial Ovarian CarcinomaPancreas Adenocarcinoma
Massachusetts General Hospital350 enrolled2 locationsNCT05470920
Recruiting
Not Applicable

Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas

Pancreas Adenocarcinomas
Central Hospital, Nancy, France120 enrolled1 locationNCT06842303
Recruiting
Not Applicable

Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy

Pancreas CancerPancreas AdenocarcinomaPancreatic Fistula+4 more
Minia University100 enrolled1 locationNCT07022015
Recruiting
Not Applicable

Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy

Pancreas CancerPancreas AdenocarcinomaPancreaticoduodenal Lymphadenopathy
Humanitas Hospital, Italy180 enrolled1 locationNCT04571294
Recruiting

The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer

Pancreas AdenocarcinomaMicroRNA
National Taiwan University Hospital30 enrolled1 locationNCT06497777
Recruiting
Not Applicable

Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX

Pancreas CancerPancreas AdenocarcinomaPancreas Metastases
Laval University15 enrolled1 locationNCT06349278
Recruiting
Phase 2

NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101

Pancreas Adenocarcinoma
Leiden University Medical Center20 enrolled1 locationNCT05984810
Recruiting

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

Pancreas Adenocarcinoma
Cure 511,020 enrolled1 locationNCT06160596
Recruiting
Not Applicable

Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer

Lymph Node MetastasisPancreas CancerPancreas Adenocarcinoma
Jon Unosson300 enrolled6 locationsNCT06065891
Recruiting

Improving Pancreatic Cancer Care by the Use of Computational Science and Technology

Pancreatic CancerPancreatic AdenocarcinomaPancreas Adenocarcinoma+3 more
UMC Utrecht5,000 enrolled1 locationNCT06055010
Recruiting
Not Applicable

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma
Capital Health System, Inc10 enrolled1 locationNCT04998552
Recruiting

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

SurgeryQuality of LifePancreas Cancer+6 more
Umeå University300 enrolled1 locationNCT05356039